Cellular Responses to Anticancer Drugs

• 2924 · PDF ζ-Stat 通过靶向 PKC-ζ/Cx43 信号通路并诱导衰老来抑制多形性胶质母细胞瘤的进展 ζ-Stat inhibits glioblastoma multiforme progression by targeting PKC-ζ/Cx43 signaling and inducing senescence Grazielly Teodoro, Shreejana Rimal, Wishrawana S. Ratnayake, Abigail Olatunji, Mildred Acevedo-Duncan
• 2925 · PDF 选择性 CDC7 抑制剂 Monzosertib 通过 FOXM1-cyclin B1 轴促进的过早有丝分裂诱导细胞死亡 Monzosertib, a selective CDC7 inhibitor, induces cell death via premature mitosis promoted by the FOXM1-cyclinB1 axis Hiroko Endo, Yu Nishioka, Mariko Hatakeyama, Youichi Tajima, Sayuri Ito, Akinori Arimura, Hisao Masai, Masaaki Sawa
• 2926 · PDF 选择性 Bcl-2 抑制剂 Sonrotoclax（BGB-11417）在血液肿瘤细胞、异种移植瘤和人全血中表现出优于 Venetoclax（Ven）和 Lisaftoclax（APG-2575）的疗效 Sonrotoclax (BGB-11417), a selective Bcl-2 inhibitor, demonstrates better efficacy than Venetoclax (Ven) and Lisaftoclax (APG-2575) in hematological cancer cells, xenografts, and human bloods Haitao Wang, Lin Li, Yiwen Wang, Hao Wang, Weiwei Song, Shuang Peng, Sijia Zhai, Ziyu Jia, Peng Chi, Xiaoyu Feng, Teiko Sumiyoshi, Wei Jin, Zhirong Shen
• 2927 · PDF G6PD 缺陷与天冬酰胺酶用于结直肠癌治疗的合成致死 Synthetic lethality of G6PD deficiency and asparaginase for colorectal cancer therapy Yun-Cheol Chae, Alan Wong, Su Hyun Lee, Anais Barthe, Meaghan McGuinness, Samantha Fitzgerald, Sima Jeha, Seth Karol, Kimmie Ng, Marios Giannakis, Naama Kanarek, Alejandro Gutierrez
• 2928 · PDF KRAS 抑制诱导的 GSDME 介导的细胞焦亡及其在 KRAS 突变肺癌中通过 LAT1 抑制的增强 KRAS inhibition-induced GSDME-mediated pyroptosis and its augmentation by LAT1 inhibition in KRAS-mutant lung cancer Kenji Morimoto, Ju Hwan Cho, Po-Lan Su, Peiran Xu, Andrew Barnes, Rahul Shivahare, Jacob Kaufman, Zihai Li, David Paul Carbone, Kai He
• 2929 · PDF sotorasib 联合 panitumumab 在 KRAS G12C 突变结直肠癌中的免疫和药效学效应：CodeBreaK 101 的配对活检结果 Immune and pharmacodynamic effects of sotorasib plus panitumumab in KRAS G12C-mutant colorectal cancer: Paired biopsy results from CodeBreaK 101 David Hong, Lata Mukundan, Abraham Anderson, Emily Chan, Dorothy French, Linnea Haeggblom, Daniel Lu, Toshiki Masuishi, Rona Yaeger, Yuliya Katlinskaya
• 2930 · PDF 揭示药物反应的决定因素：对数百种肿瘤治疗药物的 PRISM 活力分析揭示选择性和机制的介导因素 Unraveling determinants of drug response: PRISM viability profiling of hundreds of oncology therapeutics reveals mediators of selectivity and mechanism Matthew G. Rees, Mustafa Kocak, Matthew J. Emmett, Colleen T. Harrington, Li Wang, Anthony Fazio, Alvin Kalathungal, Dennie T. Frederick, Aydin Golabi, Rachael Barry, Emily Reeves, John Davis, Melissa M. Ronan, Laura Doherty, Jillian N. Eskra, William R. Sellers, Jennifer A. Roth
• 2931 · PDF RC108（一种靶向c-Met的ADC）相比Teliso-V在cMet高表达与HGF依赖性肿瘤细胞之间表现出差异性细胞毒性，提示其潜在的安全性优势 RC108, a c-Met-targeting ADC, exhibits differential cytotoxicity between cMet-high and HGF-dependent tumor cells compared with Teliso-V, suggesting a potential safety advantage Jiayue Geng, Zhanjiao Yu, Haiqing Zhong, Qingbo Wang, Xiao Lv, Tongyu Xiao, Kailin Wang, Xiaoping Zhang, Xiaoli He, Lili Wang, Ying Jiang, Jianing Liu, Yinghao Xin, Jianmin Fang, Yuanhao Li
• 2932 · PDF miRNA-379-5p与miRNA-125a-3p联合用于治疗铂耐药卵巢癌 Combination of miRNA-379-5p and miRNA-125a-3p for the treatment of platinum resistant ovarian cancer Serenade Trevino, Trey Zepeda, Sue Anne Chew
• 2933 · PDF Itareparib：一种强效、选择性且非捕获型的PARP1抑制剂，用于与DNA损伤剂联合治疗实体瘤 Itareparib: A potent, selective and non-trapper PARP1 inhibitor for combination therapy with DNA damaging agents in solid tumors Alessandro Galbiati, Gianluca Papeo, Nilla Avanzi, Fabio Gasparri, Claudia Perrera, Gemma Texido, Lisa Mahnke, Shiho Nakano, Kang Jin Jeong, Gordon B. Mills, Junko Murai, Alessia Montagnoli
• 2934 2934 表征晚期前列腺癌中PARP抑制剂治疗联合方案的反应 Characterizing response to PARP inhibitor treatment combinations in advanced prostate cancer Bryan Correa Gonzalez, Akshaya Karthikeyan, Love A. Moore, Ethan Sandoval, Anamitra Bhuamik, Marion Hardy, Alan P. Lombard
• 2935 · PDF 建立用于测量抗体药物偶联物（ADC）旁观者效应的乳腺癌实验模型 Establishment of experimental model for measuring antibody-drug conjugate (ADC) bystander effects in breast cancer Hyunmyoung Yun, Won-Ji Ryu, Hyein Jung, Tae Yeong Kim, Cheol-Hwa Hong, Yumi Hwang, Hyun Ju Han, Geon-Uk Kim, Seo Young Lee, Kyoo Hyun Kim, Min Hwan Kim, Gun Min Kim, Joo Hyuk Sohn
• 2936 · PDF NAMPT抑制增强标准化疗和免疫调节在胰腺导管腺癌中的疗效 NAMPT inhibition enhances the efficacy of standard chemotherapies and immunomodulation in pancreatic ductal adenocarcinoma Purnachandra Nagaraju Ganji, Sujith Sarvesh, Dhana Sekhar Reddy Bandi, Husain Yar Khan, Irfana Muqbil, Amro Aboukameel, Sahar Bannoura, Khalil Choucair, Walid Sukkari, Sunil Jaiman, Rafic Beydoun, Gergory Dyson, Yang Shi, N. Vaishampayan, Eliza W. Bael, Miguel Tobon, Steve Kim, Herbert Chen, Muhammad W. Saif, Anthony Frank Shields, Philip A. Philip, Min Wu, Michael Schelle, Boris Pasche, Asfar S. Azmi, Bassel F. El-Rayes
• 2937 · PDF Imipridone类药物ONC201、ONC206和ONC212对小细胞肺癌细胞系表现出强效杀伤和集落阻滞 Imipridones ONC201, ONC206, and ONC212 show potent killing and colony arrest of small-cell lung cancer cell lines Audrey Y. Su, Connor Purcell, Shengliang Zhang, Lanlan Zhou, Ashley S. Uruchurtu, Wafik S. El-Deiry
• 2938 · PDF 癌症中的KRAS和ERK5信号通路：对靶向治疗的意义 KRAS and ERK5 signaling pathways in cancer: Implications for targeted therapy Christophe Marcireau, Fréderic Lacroix, Fatima Amor, Karine Dobrazix, Guillaume Nurit, Véronique Jean-Baptiste, Eiwen Yang, Donald Jackson, Colette Dib, Gaelle Muzard, Franck Slowinski, Laurent Debussche, Pawel K. Mazur
• 2939 2939 染色体外DNA的可塑性使癌症适应药物治疗形成新的演化轨迹 Extrachromosomal DNA plasticity enables novel trajectories of cancer adaptation to drug treatments Jingting Chen, Joseph M. Dahl, Poorya Behnamie, Elizabeth Brunk
• 2940 · PDF 利用新一代1型RAF抑制剂实现肿瘤选择性的二聚体和单体RAF靶向 Tumor-selective dimeric and monomeric RAF targeting with a next-generation Type 1 RAF inhibitor Mathieu Desaunay, Tara L. Peters, Evangelia Matenoglou, Beau Baars, Bijaya Gaire, Ana Orive-Ramos, Li Ren, Joseph P. Lyssikatos, Michael R. Burkard, Dalton Dacus, Matthew J. Sale, Stuart A. Aaronson, Frank McCormick, Evripidis Gavathiotis, Stefan D. Gross, Poulikos I. Poulikakos
• 2941 · PDF 药理浓度抗坏血酸通过ROS依赖的代谢脆弱性在MYCN扩增的神经母细胞瘤中发挥抗癌活性 Pharmacologic ascorbate exerts anticancer activity through ROS-dependent metabolic vulnerability in MYCN-amplified neuroblastoma Tasfia Farah, Qi Chen
• 2942 · PDF 通过SSI-4抑制硬脂酰辅酶A去饱和酶1（SCD1）作为非小细胞肺癌的治疗策略 Inhibition of stearoyl-CoA desaturase 1 (SCD1) by SSI-4 as a therapeutic strategy in non-small cell lung cancer Valeria Romina Salerno Gonzales, Lauren Antal, Tamiel Nichole Turley, John A. Copland III
• 2943 · PDF TROP2靶向抗体药物偶联物datopotamab deruxtecan（Dato-DXd）在乳腺癌细胞系中与DNA损伤反应相关的抗肿瘤作用 Antitumor effect of TROP2-targeted antibody drug conjugate, datopotamab deruxtecan (Dato-DXd), in association with DNA damage response in breast cancer cell lines Seohyeon Lim, Sujin Ham, Hae Min Hwang, Youlim Noh, Jiwon Koh, Chaeyoung Lee, Minyoung Jeong, Yu-Jin Kim, Minyoung Lee, Sohyeon Kim, Changhee Park, Dae-Won Lee, Kyung-Hun Lee, Seock-Ah Im
• 2944 · PDF 揭示透明细胞卵巢癌中对THZ1的锌依赖性反应和耐药通路 Uncovering the zinc-dependent pathways of response and resistance to THZ1 in clear cell ovarian cancer Maya Modak, Soledad Ochoa, Forough Abbasi, Dandi Huang, Robbin Nameki, BJ Rimel, Kate Lawrenson
• 2945 · PDF 靶向肌动蛋白-微管网络完整性以增强前列腺癌中紫杉烷类药物-靶点结合和化疗敏感性 Target actin-microtubule network integrity to enhance taxane drug-target engagement and chemosensitivity in prostate cancer Felipe Carvolho, Tanvi Desai, Keira Ly, Joubin Jebelli, Ajay Bommareddy, Jianning Wei, Michael L. Lu
• 2946 · PDF RQ43：一种抑制胰腺癌细胞EMT和迁移的喹啉衍生物 RQ43: A quinoline derivative that inhibits pancreatic cancer cell EMT and migration Sreyoshi Das, Qi Chen
• 2947 2947 抑制NRF2驱动的抗氧化防御与EMT是brusatol诱导宫颈癌细胞毒性的基础 Inhibition of NRF2 driven antioxidant defence and EMT underlies brusatol induced cytotoxicity in cervical cancer cells Gunjan Dagar, Mohd Umar Rehmani, Teena Haritwal, Ajaz A. Bhat, Mayank Singh
• 2948 · PDF RAF/MEK胶通过对RAF的空间捕获机制实现与pan-RAF抑制剂的全剂量联用，并驱动强效的、RAS突变肿瘤选择性的MAPK抑制及生长抑制 A spatial-trapping mechanism of RAF by RAF/MEK glue enables full-dose combination with a pan-RAF inhibitor and drives potent, RAS-mutant tumor-selective MAPK and growth inhibition Bijaya Gaire, Ana Orive-Ramos, Christos Adamopoulos, Beau Baars, Mathieu Desaunay, Evangelia Matenoglou, Silvia Coma, Nayeli Gutierrez-Trejo, Kevin Mohammed, Stuart A. Aaronson, Jian Jin, Tiphaine Martin, Ernesto Guccione, Evripidis Gavathiotis, Jonathan A. Pachter, Poulikos I. Poulikakos
• 2949 · PDF Palazestrant（一种CERAN）与OP-3136（一种KAT6抑制剂）联用可协同下调细胞增殖及转移相关基因特征 Palazestrant, a CERAN, in combination with OP-3136, a KAT6 inhibitor, synergistically downregulates cell proliferation and metastasis related gene signatures Susanna A. Barratt, Gopinath S. Palanisamy, Azita Ghodssi, Chelsea Hope, Guadelupe Peña, Srinivasan Jayaraman, Raymond A. Ng, David C. Myles
• 2950 · PDF Palazestrant在体外直接募集辅阻遏蛋白NCoR1，从而完全拮抗雌激素受体alpha Palazestrant directly recruits the corepressor protein NCoR1 in vitro leading to complete antagonism of estrogen receptor alpha Susanna A. Barratt, Guadelupe Peña, Chelsea Hope, Gopinath S. Palanisamy, Raymond A. Ng, David C. Myles
• 2951 · PDF RAS突变肿瘤对突变及状态选择性RAS抑制剂反应的适应性与获得性机制 Adaptive and acquired mechanisms underlying RAS-mutant tumor response to mutant and state selective RAS inhibitors Ziyue Kou, Bijaya Gaire, Beau Baars, Mathieu Desaunay, Poulikos I. Poulikakos

在会议检索中浏览本分会场